72 results
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
, responsible for the global clinical development of sorafenib (Nexavar ® ) at Bayer. Former CEO of PROLOR Biotech. Founding team and Director of R&D
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
29 Mar 24
Report of Foreign Private Issuer
4:30pm
financial statements include the accounts of the Company and Enlivex Therapeutics R&D Ltd. and Enlivex Therapeutics RDO Ltd., its wholly owned subsidiaries … to operate in the foreseeable future. The functional currency of Enlivex Therapeutics R&D Ltd. was the New Israeli Shekel (“NIS”) until September 30
6-K
EX-99.1
p9g kkeyqis5
4 Apr 23
Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates
8:05am
6-K
EX-99.1
xji831dccwmv 8o
31 Mar 23
Report of Foreign Private Issuer
4:30pm
424B5
c5lqtq eu
30 Dec 22
Prospectus supplement for primary offering
4:01pm
6-K
EX-99.1
aejc6c2o9gg74
5 Dec 22
Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update
8:05am
6-K
EX-99.1
fnme be4qcma
2 Dec 22
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.2
vafdl0rv3t
2 Dec 22
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.1
e4n41983i7
24 Aug 22
Report of Foreign Private Issuer
8:05am
6-K
EX-99.2
5bbh67
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
6-K
EX-99.3
oxdrm7ft
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
6-K
EX-99.1
cey9clf
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
6-K
EX-99.1
cdedqw7t
27 May 22
Condensed Consolidated Financial Statements
4:39pm
6-K
EX-99.2
jl2rndqxb1a9smvh
27 May 22
Condensed Consolidated Financial Statements
4:39pm
6-K
EX-99.1
6nqk82pk
29 Apr 22
Report of Foreign Private Issuer
8:15am